This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Experienced Surgeon Vs. FDA-Approved Robot

NEW YORK, April 11, 2013 /PRNewswire/ -- With more than 4,500 robotic prostate surgeries under his belt, David Samadi, MD may be the last person you'd expect to welcome an FDA investigation of robotic surgery. But late Tuesday he appeared on Fox 5 News saying, "Let the FDA do their investigation and clear the air. This is about our prostate cancer patients."

(Photo: http://photos.prnewswire.com/prnh/20130411/NY93298 )

Dr. David Samadi is Vice Chairman of the Department of Urology and Chief of Robotics and Minimally Invasive Surgery at Mount Sinai Medical Center. He was among the first in the world to perform robotic prostate surgery and today he uses the da Vinici robot in his highly successful SMART (Samadi Modified Advanced Robotic Technique) version of the procedure.

Dr. Samadi offers these key questions for patients to ask their prospective surgeon:

  1. How many successful robotic surgeries have you performed?
  2. Will I be your only patient/operating room during my procedure?
  3. What are the typical complications following your robotic surgeries?

Over the past few years, hospitals have invested big money in procuring and promoting surgical robots, but enthusiasm for the technology may be waning amid reports of robotic surgery mistakes and deaths. In 2012, the nationwide count for robotic surgeries hit almost 400,000. Some experts say more robotic procedures are bound to result in increased data on negative surgical outcomes. But is it really a matter of odds or just an excuse for surgeon inexperience and limited training requirements?

Dr. Samadi stands by the robot, instead directing patient focus to the surgeon and the hospital. Stressing the surgeon-robot duo he says, "The technology is safe; you have to know how to use it."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs